๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Suzhou 8 Hangzhou 5 Tianjin 4 Chongqing 4
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Suzhou8 Hangzhou5 Tianjin4 Chongqing4
All 27 locations
Target enrolment
to

Trials with a site in Hangzhou

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
NCT07483749Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Observational
400
Hangzhou, Ningbo
2026-03-25
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Recruiting
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
NCT04532281Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
Zhejiang University
Phase EARLY_PHASE1
120
Hangzhou
2020-11-01
Recruiting
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
NCT04532203Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Zhejiang University
Phase EARLY_PHASE1
72
Hangzhou
2020-11-01
Recruiting
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
He Huang
Phase EARLY_PHASE1
72
Hangzhou
2020-01-08
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

3 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 5 studies
PhaseStudiesRecruitingShare
Phase EARLY_PHASE13360%
Observational1020%
Phase 11020%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Zhejiang University22
He Huang11
Sichuan Baili Pharmaceutical Co., Ltd.10
The Children's Hospital of Zhejiang University School of Medicine10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.